Movement Alert｜Akeso Inc Falls 4.49% in Regular Trading, Large Block Sale Triggers Profit-Taking After ASCO Rally

Market Focus06-02

On June 2, Akeso Inc fell 4.49% in regular trading, trading at 108.8 HKD/share, with trading volume of HKD 1.06 billion. The stock faced selling pressure following a large block trade of 250,000 shares worth approximately HKD 29 million executed during early trading hours.

The decline comes as a reversal after the stock surged nearly 10% on June 1, when its core product ivonescimab demonstrated a 34% reduction in death risk in the Phase III HARMONi-6 study presented at the ASCO plenary session. Northbound funds had net purchased over HKD 2.7 billion of the stock on that day. However, the large block sale combined with a broader pullback across the biotech sector weighed on sentiment.

Within the Biotechnology sector, peers also declined broadly, with 3SBIO down 7.78%, SKB Bio down 6.66%, Remegen down 4.40%, Innovent Bio down 4.08%, and BeiGene down 3.03%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151560139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151560139","market":"us","top_or_hot":-1,"title":"Movement Alert｜Akeso Inc Falls 4.49% in Regular Trading, Large Block Sale Triggers Profit-Taking After ASCO Rally","media":"Market Focus","content":"<p><p>On June 2, Akeso Inc fell 4.49% in regular trading, trading at 108.8 HKD/share, with trading volume of HKD 1.06 billion. The stock faced selling pressure following a large block trade of 250,000 shares worth approximately HKD 29 million executed during early trading hours.</p><p>The decline comes as a reversal after the stock surged nearly 10% on June 1, when its core product ivonescimab demonstrated a 34% reduction in death risk in the Phase III HARMONi-6 study presented at the ASCO plenary session. Northbound funds had net purchased over HKD 2.7 billion of the stock on that day. However, the large block sale combined with a broader pullback across the biotech sector weighed on sentiment.</p><p>Within the Biotechnology sector, peers also declined broadly, with 3SBIO down 7.78%, SKB Bio down 6.66%, Remegen down 4.40%, Innovent Bio down 4.08%, and BeiGene down 3.03%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Inc Falls 4.49% in Regular Trading, Large Block Sale Triggers Profit-Taking After ASCO Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Inc Falls 4.49% in Regular Trading, Large Block Sale Triggers Profit-Taking After ASCO Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-02 09:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 2, Akeso Inc fell 4.49% in regular trading, trading at 108.8 HKD/share, with trading volume of HKD 1.06 billion. The stock faced selling pressure following a large block trade of 250,000 shares worth approximately HKD 29 million executed during early trading hours.</p><p>The decline comes as a reversal after the stock surged nearly 10% on June 1, when its core product ivonescimab demonstrated a 34% reduction in death risk in the Phase III HARMONi-6 study presented at the ASCO plenary session. Northbound funds had net purchased over HKD 2.7 billion of the stock on that day. However, the large block sale combined with a broader pullback across the biotech sector weighed on sentiment.</p><p>Within the Biotechnology sector, peers also declined broadly, with 3SBIO down 7.78%, SKB Bio down 6.66%, Remegen down 4.40%, Innovent Bio down 4.08%, and BeiGene down 3.03%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1151560139","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151560139","pubTimestamp":1780364784,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 2, Akeso Inc fell 4.49% in regular trading, trading at 108.8 HKD/share, with trading volume of HKD 1.06 billion. The stock faced selling pressure following a large block trade of 250,000...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势提示|康方生物常规交易下跌4.49%ASCO反弹后大宗抛售引发获利了结","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On June 2, Akeso Inc fell 4.49% in regular trading, trading at 108.8 HKD/share, with trading volume of HKD 1.06 billion. The stock faced selling pressure following a large block trade of 250,000 shares worth approximately HKD 29 million executed during early trading hours.The decline comes as a reversal after the stock surged nearly 10% on June 1, when its core product ivonescimab demonstrated a 34% reduction in death risk in the Phase III HARMONi-6 study presented at the ASCO plenary session. Northbound funds had net purchased over HKD 2.7 billion of the stock on that day. However, the large block sale combined with a broader pullback across the biotech sector weighed on sentiment.Within the Biotechnology sector, peers also declined broadly, with 3SBIO down 7.78%, SKB Bio down 6.66%, Remegen down 4.40%, Innovent Bio down 4.08%, and BeiGene down 3.03%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151560139","isCrawlerRequest":true}